Detalhe da pesquisa
1.
Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
N Engl J Med
; 387(26): 2411-2424, 2022 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516078
2.
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
J Infect Dis
; 229(4): 1068-1076, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673423
3.
Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Clin Infect Dis
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657084
4.
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
EMBO J
; 38(14): e101564, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31304633
5.
The histone methyltransferase DOT1L prevents antigen-independent differentiation and safeguards epigenetic identity of CD8+ T cells.
Proc Natl Acad Sci U S A
; 117(34): 20706-20716, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32764145
6.
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
J Pathol
; 250(2): 134-147, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31518438
7.
Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance.
FASEB J
; 31(5): 2195-2209, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28183801
8.
HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis.
FASEB J
; 29(5): 2070-80, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25648995
9.
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Hum Vaccin Immunother
; 20(1): 2327747, 2024 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38523332
10.
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Lancet Infect Dis
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38552653
11.
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
NPJ Vaccines
; 8(1): 174, 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940656
12.
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.
Cell Rep
; 42(9): 113101, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691146
13.
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Front Immunol
; 14: 1215302, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37727795
14.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
EBioMedicine
; 91: 104562, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099841
15.
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Vaccine
; 41(50): 7573-7580, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981473
16.
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Lancet Infect Dis
; 23(3): 352-360, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273490
17.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Lancet Glob Health
; 11(11): e1743-e1752, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37858585
18.
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
PLoS One
; 17(10): e0274906, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36197845
19.
Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus.
PLoS Genet
; 4(8): e1000145, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18670629
20.
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
Nat Commun
; 11(1): 3157, 2020 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32572029